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Tuberculosis is a bacterial infectious disease that is mainly transmitted from
human to human via infectious aerosols. Currently, tuberculosis is the leading cause
of death by an infectious disease world-wide. In the past decade, the number of
patients affected by tuberculosis has increased by ∼20 percent and the emergence of
drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination
of tuberculosis in the near future. For the last 50 years, management of patients with
tuberculosis has followed a standardized management approach. This standardization
neglects the variation in human susceptibility to infection, immune response, the
pharmacokinetics of drugs, and the individual duration of treatment needed to achieve
relapse-free cure. Here we propose a package of precision medicine-guided therapies
that has the prospect to drive clinical management decisions, based on both host
immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries
and technological advances have been achieved that provide a perspective for
individualized rather than standardized management of patients with tuberculosis. For
the individual selection of best medicines and host-directed therapies, personalized drug
dosing, and treatment durations, physicians treating patients with tuberculosis will be
able to rely on these advances in systems biology and to apply them at the bedside.
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INTRODUCTION
Tuberculosis is the leading cause of death attributed to a
single microbial pathogen world-wide (1). The World Health
Organization (WHO) estimates, that in the year 2018 globally
10 million people newly developed tuberculosis and 1.5 million
people died from this disease (1). Despite the enormous
burden of tuberculosis on healthcare systems, especially in
developing countries, research on new preventive and diagnostic
methods and novel therapies against tuberculosis has gained new
momentum only recently.
For the past five decades, patients with tuberculosis have
received the same standard therapies without acknowledging
differences in human immunity, pharmacokinetics or variations
in the pathogenesis or of the causative microbe, Mycobacterium
tuberculosis. Treatment was empiric or adopted to results of
phenotypic drug-susceptibility testing that takes several weeks
to months to become available. Patient-tailoring was limited to
adjusting dosing to body weight, mostly in pediatric patients (2).
FIGURE 1 | In the near future, Precision Medicine for tuberculosis will likely include (I) antibiotic regimens based on next-generation sequencing of the Mycobacterium
tuberculosis genome to guide tailor-made therapies; (II) evaluation of gene expression, genetic, epigenetic, metabolism, and/ or immune phenotyping to discern the
host endotype with endotype-specific host directed therapies to shorten and improve clinical outcomes; (III) individualization of antibiotic dosing through therapeutic
drug monitoring; (IV) in treatment biomarker levels to customize therapy duration. LAM, lipoarabinomannan; Mtb, Mycobacterium tuberculosis; INH, isoniazid; LSS,
limited sampling strategy; HPLC-MS, high-performance liquid chromatography-mass spectrometry; AUC, area under the curve; MIC, minimal inhibitory concentration;
TB, tuberculosis.
We have now entered an exciting era of medicine with major
advances in the field of system biology and there is a realistic
perspective that patients with tuberculosis will substantially
benefit from these developments (3–5).
In the future, tuberculosis patient care may be individualized
in at least 4 areas (Figure 1): (I) next generation sequencing of
microbial M. tuberculosis DNA can predict drug susceptibility
in the first week of diagnosis (6); (II) host immunity can
be detrimentally suppressed and need augmenting or it can
be detrimentally exuberant and need to be suppressed (7–
9); or other forms of host genetic variability that may be
specifically addressed by immune-based interventions (10), (III)
individualized drug concentrations that can guide antimicrobial
dosing (11), and (IV) biomarkers that predict relapse-free cure
and can guide duration of required therapeutics (12) (Figure 1).
Such stratified therapies are within reach and could soon become
available for the clinical management of tuberculosis.
Precision Medicine refers to prevention and treatment
strategies that take individual variability into account and predict,
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who will benefit most from specific therapies and who will not.
Taken together, PrecisionMedicine will improve patient outcome
and reduce cost.
SUBSECTIONS RELEVANT FOR THE
SUBJECT
I: Design of Tailor-Made Treatment
Regimens Based on Mycobacterial
Genotypes
Drug resistances in M. tuberculosis complex strains are
exclusively mediated by genomic variants, mainly single
nucleotide polymorphisms (SNPs) and small insertions/deletion
(indels). Acquisition of resistance genes via plasmids or
horizontal gene transfer does not occur (13). Accordingly,
resistant phenotypes of M. tuberculosis complex strains mainly
have a clear genetic correlate, which means SNPs can be used for
resistance predictions with very high precision and are expected
to replace phenotypic drug susceptibility testing (DST) in the
future (13). The virtually complete interrogation of all resistance
associated variants in genomes of clinicalM. tuberculosis complex
strains has become possible by advances of next generation
sequencing (NGS) techniques. NGS allows for rapid sequencing
of full genomes or targeted sequencing of resistance genes
(amplicon sequencing) even directly from patient specimens,
i.e., sputum (14–16). While genomic variant detection is
of very high accuracy, genotypic drug susceptibility testing
performance is strongly dependent on the underlying knowledge
database (17). Although there is no standardized and globally
adopted, “resistance mutation catalog” available yet, recent
studies demonstrate that genotypic DST can predict resistance
to the first-line drugs isoniazid, rifampicin, pyrazinamide with
more than 90% sensitivity and more than 95% specificity, and
thus would meet the WHO target product profile for molecular
DST assays (6, 18). However, resistance prediction for some
drugs, such as ethambutol and pyrazinamide is problematic due
to breakpoint artifacts in phenotypic DSTs (19) or gaps in current
knowledge databases, i.e., yet unknown resistance mutations.
There is emerging evidence that genotypic DST has a very
good prediction for phenotypic drug susceptibility (20, 21)
although for some drugs like PAS, D-cycloserine, thioamides,
linezolid, meropenem-clavulanate, bedaquiline, clofazimine, and
delamanid data are still limited. Programmes aiming to fill the
knowledge gap in “geno-to-pheno” prediction such as CRyPTIC
(www.crypticproject.org) and ReSeqTB (platform.reseqtb.org)
are currently collecting genome sequencing data of global strain
collection in combination with phenotypic DST data to further
improve genotypic resistance predictions. Here, sequencing
approaches represent an effective alternative to rapidly generate
comprehensive resistance profiles of multidrug-resistant (MDR)
strains allowing the design of a successful MDR-TB therapy for
around 90% of the MDR-TB patients (18, 20).
Genotypic DST methods already provide accurate predictions
for first-line anti-tuberculosis drugs and guide the design of
MDR-TB therapies (6, 20). Sputum sequencing together with
an improved interpretation catalog of drug resistance defining
mutations will potentially allow genotypic DST to replace
phenotypic DST for a large fraction of clinical M. tuberculosis
complex strains.
II: Endotype-Guided Host Directed
Therapies and Host Genetic Variability
Tuberculosis endotypes are the distinct molecular pathways
through which an individual can progress to active tuberculosis.
In a rough generalization, tuberculosis host immunity endotypes
can be classified as immune deficient or as immune exuberant.
The best described tuberculosis endotypes are deficiencies in
interleukin (IL)-12, interferon (IFN)-γ or tumor necrosis factor
(TNF) pathways, which result in decreased intracellular killing
of M. tuberculosis (22, 23). However, mouse and human studies
also demonstrated that exuberant IFN-γ or TNF is detrimental,
resulting in pulmonary and macrophage necrosis and the escape
of viableM. tuberculosis into extracellular space (8, 24–26). These
studies demonstrate that a single immune correlate of protection
is unlikely to be identified as the host immunity can not be
either deficient or overly exuberant. Therefore, implementation
of host-directed therapies (HDT) should preferably not be
indiscriminate, but needs to be guided by the tuberculosis
immune endotype. Preliminary work supports the identification
of divergent host endotypes with contradictory metabolic,
epigenetic, and immune gene expression endotypes (7), but these
transcriptional studies lack corresponding functional studies.
In the pre-antibiotic era, treatment for tuberculosis was
limited to host-directed therapy aiming at improving the
nutritional and immune status of patients, e.g., with cod liver
oil and sunlight (27), resulting in ∼20% survival rate for a
period of at least 10 years (28). Harnessing and targeting
host immunity, while minimizing immunopathology is the
critical next phase in improving anti-tuberculosis therapy.
Implementing endotype-specific host-directed therapy, first
require proper characterization of the distinct tuberculosis
endotypes in order to identify amendable targets. Tuberculosis
dampens host immune responsiveness (29–33), and therefore
transcriptomic and immune functional studies must be
implemented both at baseline and upon antigenic stimulation.
Since 1927, we have known that metabolism drives immunity
(34) and modern studies are defining the metabolic-epigenetic-
immune axis (35–39). Therefore, ideally, transcriptomic,
metabolic, epigenetic and functional immune studies would
be paired with robust clinical information that would allow
for multi-modal data integration between molecular data and
clinical outcomes. Finally, an immune deficient vs. immune
exuberant model, while helpful, is overly simplistic as single cell
studies have demonstrated deficiency in one arm of immunity,
while exuberance in another. For example, tuberculosis
induced hemophagocytic lymphohistiocytosis (HLH) is
characterized by exuberant monocytes and deficient cytotoxic
lymphocytes (40–43).
Endotype characterization studies likely will need to occur
at disease diagnosis and again weeks into therapy. Tuberculosis
is the archetypical chronic infection, hence host immunity
after months of chronic antigenic stimulation is unlikely to
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resemble host immunity at the beginning of infection. Upon
initial antigenic stimulation, modulated by inositol triphosphate
receptors, there is an influx of calcium that helps stimulate
glycolysis and activates nuclear factor of activated T-cells (NFAT)
to translocate into the nucleus (44) as an example.When immune
activation is chronic, NFAT switches from heterodimerizing with
activator protein (AP)-1, to forming homodimers that drive
anergy and thymocyte selection-associated high mobility group
box protein TOX (TOX) and nuclear receptor 4A (NR4A)
and epigenetic-mediated immune exhaustion (45–50). Therefore,
drugs that modulate calcineurin-NFAT, such as cyclosporin A or
tacrolimus, could detrimentally inhibit host immunity early in
the disease process by blocking AP-1-NFAT heterodimers that
drive beneficial immunity. In contrast, late in the disease process,
these same drugs may be beneficial by blocking the detrimental
NFAT homodimers that drive anergic and immune exhaustion
responses. Evaluating endotypes could be operationalized by
tests such as a mycobacterial growth inhibition assay, a test
that has identified ∼50% of tuberculosis patients to have good
mycobacterial killing capacity and∼50% to have deficient killing
capacity (51), and an ELISA based test, such as a modified
version of the QuantiFERON-TB Gold in-tube assay or T-
SPOT.TB assay.
Host genetic studies have thus far largely focused on
susceptibility to active tuberculosis (52, 53), to a lesser extent
on susceptibility to infection (54) while the relationship
between host genetic variability and treatment outcome is
largely unexplored.
With regard to anti-tuberculous treatment, genetic
studies have focused on drug exposure and toxicity
(“pharmacogenetics”). The strongest association established
is between N-acetyltransferase (NAT)2-acetylator status and
isoniazid drug concentrations, microbiological failure, relapse
(55), and hepatotoxicity (56) and probably, genetic variation
underlies rifampicin bioavailability and aminoglycoside-
induced hearing loss (10). A next step would be “Mendelian
randomization” studies: associating genetic loci predicting drug
concentrations to treatment outcome (rather than toxicity).
Then, pharmacogenetic trials could be initiated in which patients
are randomized to standard treatment vs. genotype-based
drug dosing.
In the most extreme disease phenotypes, targeted HDT
may be most relevant. A Leukotriene A4 hydrolase (LTA4H)
promotor genotype, important for the balance between pro-
and anti-inflammatory eicosanoids (24), predicted cerebrospinal
fluid leukocyte count. The hyper-inflammatory genotype was
associated with improved survival in HIV-negative patients
receiving corticosteroids (57, 58). In contrast, the same LTA4H
genotype did not predict mortality in another cohort of patients
(59), possibly because of higher disease severity, but the
conflicting results could also be driven by genetic factors such
as shorter regions of linkage disequilibrium or plasticity in the
direction of the effect of the polymorphism (60). This shows that
host genetic studies should be replicated in different settings.
This can result in randomized controlled trials with stratification
according to genotype, as is currently done in a study among
patients with tuberculous meningitis, where only those with the
hypo-inflammatory LTA4H genotype are randomized to receive
corticosteroids or placebo (and all with a hyperinflammatory
genotype receive corticosteroids) (61).
Genetic studies can be strengthened by an integrated or
“cross-omics” approach. Among patients with tuberculous
meningitis, using unbiased metabolomics, it was found that
higher cerebrospinal fluid tryptophan, which can affect M.
tuberculosis growth and central nervous system inflammation,
was associated with higher mortality. Using a genome-wide
association approach, so-called quantitative trait loci (QTLs)
that associate with cerebrospinal fluid tryptophan levels were
identified, and those same QTLs predicted survival in 285
other patients (62). The relevance of tryptophan metabolism,
its genetic regulation, and the possible implications HDT are
now being examined in more than 2,000 tuberculous meningitis
patients (https://grantome.com/grant/NIH/R01-AI145781-01).
Other “omics” data that could be used in such an integrated
approach are transcriptional data or proteomics.
Future genetic studies will also benefit from precise patient
characterization and combination with M. tuberculosis genotype
(63), in a genome-to-genome approach (64). Also, replication
studies in different settings, including relevant covariates, are
needed and promising leads need to be trailed in studies
focusing on outcome to identify genetic variants important in
treatment decisions.
III: Therapeutic Drug Monitoring
Therapeutic drug monitoring (TDM) is the concept of
individualizing drug dosing bymeasuring the drug concentration
in a patient’s serum/plasma and adjusting the dose accordingly.
Consequently, TDM is indicated in settings with a risk of low
or high tuberculosis drug exposures: presence of altered drug
absorption, distribution, metabolism, or excretion (e.g., renal
insufficiency), comorbidities that may affect exposure to anti-
tuberculosis drugs [HIV infection, diabetes mellitus (65)], drug-
drug interactions, and in patients who are slow to respond or with
relapsed tuberculosis (66).
Low anti-tuberculosis drug concentrations can lead to
inefficient mycobacterial killing, treatment failure, relapse and
selection of drug resistance (67), whereas high concentrations
may increase the risk of adverse effects (68).
The TDM process comprises (1) obtaining blood samples,
(2) measuring drug concentrations, and (3) interpreting
the results.
1. The optimal sampling time points and the number of samples
depend on the assessed drug. Limited sampling strategies
(LSS) predict the most informative sampling time points
based on population pharmacokinetic data, i.e., “average”
exposures from tuberculosis patients. With the help of LSS,
sampling can often be reduced to three or less time points
(69, 70).
2. Analysis of the serum/plasma samples is ideally performed
with high performance liquid chromatography mass
spectrometry (HPLC-MS). HPLC-MS is highly sensitive
and specific and allows simultaneous analysis of several
tuberculosis drugs in one run of the assay (71).
3. The degree of exposure that is effective depends on the
susceptibility of the patient’s M. tuberculosis strain, as
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TABLE 1 | Current standards and future perspectives for Precision Medicine for tuberculosis.
Measure Current standard Future perspective for precision medicine When to apply
Rapid selection of effective
anti-tuberculosis drugs to form a
treatment regimen.
Rapid molecular Rifampicin-resistance
testing followed by phenotypic drug
susceptibility testing in liquid and/or solid
media cultures.
Rapid, sputum-based automated sequencing of the
entire genome of M. tuberculosis or of genetic regions
(amplicons) of the genome of M. tuberculosis where
mutations do predict drug resistance. Algorithm-based
treatment decisions based on molecular prediction of
drug resistance.
At the time of
diagnosis.
Supporting the host immunity by
endotype-guided decisions for
host-directed therapies.
Endotypes of tuberculosis are still not well
defined and identification of endotypes to
guide host directed therapies is not
performed at present.
Optimal testing needs to be discerned, but likely will
include a mixture of metabolism, genetic, epigenetic
and/or immune functional studies to identify the host
endotype. For example, if host immunity was found to be
exuberant, then an endotype-specific therapy might
consist of a glucocorticoid, NSAID, calcineurin inhibitor
(cyclosporin or tacrolimus) or mTOR inhibitor
(rapamycin). In contrast, if evaluations identified anergic
or exhausted immunity, than immune boosting regimens
may be chosen.
Within the first week: of
the diagnosis.
Should be repeated
4–8 weeks to evaluate
dynamic transitions.
Analysis of host genetic
variability to predict adverse
events and to provide precise
therapeutically interventions.
Host genetic markers are currently not
identified in clinical practice. At specialized
centers and on special request genetic
markers such as mutations associated
with specific immune deficiencies are
evaluated.
Genetic testing before the start of treatment to (1) define
dosing of anti-tuberculous treatment and to (2) identify
patients susceptible to adverse drug events and (3) to
tailor host-directed therapy to the individual patient.
At the time of
diagnosis.
Therapeutic drug monitoring. Only very few centers world-wide perform
measurement of drug levels and PK/PD
profiles of anti-tuberculosis drugs in
routine clinical practice. Even at these
centers there are no analytic capacities to
monitor several of the 2nd-line
anti-tuberculosis drugs.
Regular therapeutic drug monitoring with
same-day-results for all anti-tuberculosis drugs for
individual dosage adjustments.






Individualizing the duration of
anti-tuberculosis therapy.
There are no biomarkers available for
routine clinical practice to guide clinicians
in the decision of the duration of
anti-tuberculosis therapy.
Defining the duration of therapy to achieve relapse-free
cure based on the measurement of a robust validated
biomarker that also identifies patients having the risk for
experiencing recurrent disease at early time points during




of treatment starting at
month 4.
reflected in the minimal concentration that inhibits growth
ofM. tuberculosis (minimal inhibitory concentration—MIC).
Dependent on the drug’s mode of action, targets are defined
as area under the curve (AUC)/MIC, maximal concentration
(Cmax)/MIC, or time above MIC (T>MIC). Unfortunately,
specific targets are not yet available for anti-tuberculosis
drugs and MIC is seldomly determined. Alternatively, drug
concentrations are compared to population pharmacokinetic
data (66).
Linking NGS data for prediction of minimal inhibitory
concentrations (MIC) with TDM data is a very promising
concept to provide tailored high-dosage therapies in cases of low
level bacillary drug resistance (21, 72). More clinical information
will be needed to proof the plausible assumption that mutations
in the genome of M. tuberculosis corresponding with a mildly
elevatedMICs to specific medicines can be overcome by a higher-
dose administered of these drugs.
There is a disparity between tuberculosis prevalence and
available resources for its treatment. TDM is highly resource-
intensive with limited reimbursement available to offset cost.
As health care providers avoid the costs of purchase and
maintenance of equipment without reimbursement, very few
centers have implemented TDM in their routine clinical practice.
Ideally, results should be available and interpreted within
days in order to effectively adjust therapies. New sampling
techniques (73, 74), development of automated analytical
techniques (immuno-assays) and in-vitro models that help
to substantiate target values (75) will facilitate its roll-out.
TDM integrates information on drug pharmacokinetics and
mycobacterial susceptibility to ensure efficacy and prevent
toxicity. It could improve the use of currently available drug
therapy and individualized high-dose treatments may even
overcome some forms of resistance.
IV: Biomarker Based Treatment Decisions
An ideal treatment monitoring test would have a 1–2 day turn-
around, be available and implementable in resource constrained
settings and could accurately identify when tuberculosis therapy
can be terminated to minimize excess treatment. Molecular
tests such as the GeneXpert (Cepheid, USA) or the line-probe
assays (Hain Life Sciences, Nehren, Germany) are commercially
available as rapid diagnostic methods that permit drug-resistance
prediction for important first- and second-line drugs (76, 77).
As an alternative, transrenal DNA, and lipoarabinomannan
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(LAM) detection in urine have been described to diagnose active
tuberculosis in people living with HIV (78–80). Screening for
tuberculosis with a LAM urine assay in African people living with
HIV and lowCD4 count lead to a significant decrease inmortality
(81). A novel assay with increased sensitivity may even have a
larger impact for the management of HIV-associated tuberculosis
(82). As an alternative, the detection of mycobacterial DNA from
stool samples of patients with tuberculosis highly correlated with
sputum-based diagnostic results and were also able to identify
patients at risk for experiencing therapy failure (83).
Immunological assays could improve outcomes in
populations in whom diagnosis is very difficult, such as children
in whom reports of the T-cell activation marker (TAM-TB) test
suggest a sensitivity and specificity of ∼83 and 97%, respectively
(84). Complex analysis of transcriptomic studies from whole
blood have indicated RNA signatures to be associated with future
active tuberculosis although the applicability of such tools in
a low or middle income country context is uncertain (85–87).
However, a recent systematic review and patient-level pooled
meta-analysis concluded that blood transcriptional biomarkers
reflect only short-term risk of active tuberculosis and surpass
WHO benchmarks only if applied to 3–6-month intervals (88).
In addition, certain computer-aided diagnostic (CAD) tools
may be able to identify tuberculosis patients with high accuracy
(specificity of 98% and of sensitivity 90%) from digital chest-X-
ray images (89).
Mycobacterial culture is the most relevant measure of
treatment response, but mycobacterial growth is slow and, as
treatment progresses, the time to a positive result increases
(90). Here, rapid molecular tests detecting only viable bacteria
such as the molecular bacterial load assay (MBLA) may be
promising for the future treatment monitoring of tuberculosis
patients (91). TheMBLA correlates with the time to liquid culture
positivity. The advantage is that it is rapid and not compromised
by contamination of culture. MBLA test results correlates with
disease severity, and provide information on the bactericidal
effect of different drugs and drug regimens (91–93). As a rapid
test measuring the number of viable organisms in a few hours
it has potential to identify failing patients. This could suggest
infection with a resistant organism or non-adherence and enable
additional investigations or alternatively provide reassurance that
the patient is responding appropriately. Operational trials to
explore this are now underway.
Phenotypic changes on M. tuberculosis-specific blood T cells
may be able to inform about treatment efficacy as shown in
adults and in children (94, 95). Modern imaging techniques such
as PET-CT scans may correlate with treatment responses, but
alone were not accurate enough to precisely identify patients with
recurrent disease in South Africa (96). Interestingly, certain RNA
signatures could predict recurrent disease in tuberculosis patients
(97, 98). However, these biomarkers have not been prospectively
evaluated and markers that could individualize the duration of
therapy are missing so far.
DISCUSSION
With technological advances in the field of diagnostics, analytics,
and integration of comprehensive data-sets, tailor-made
Precision Medicine for patients with tuberculosis is within
reach at centers that operate on the frontier of translational
research (Table 1). As independent measures, genotypic
prediction of phenotypic M. tuberculosis drug-resistance based
on information of entire bacterial genomes, genotypic and
phenotypic identification of immune endotypes and human
susceptibility to tuberculosis to individualize HDT, and novel
biomarkers guiding physicians for individual treatment decisions
are already in place at highly specialized centers and usually
under research conditions. The clinical application of some
of these innovations needs to become the medical standard.
However, as a poverty-related disease, the majority of patients
affected by tuberculosis live in resource limited settings.
Finding funding and performing operational research on the
implementation of precision medicine for tuberculosis in these
settings will be one of the great challenges for the future.
AUTHOR CONTRIBUTIONS
All authors made a contribution to the acquisition of the
information for the work, critically revised the manuscript
for important intellectual content, and gave final approval of
the current version to be published. All authors agree to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
FUNDING
German Center for Infection Research (DZIF) Clinical TB TTU-
TB 02.704.
ACKNOWLEDGMENTS
The publication of this article was supported by the Open Access
Publication Fund of the Leibniz Association.
REFERENCES
1. World Health Organization. Global Tuberculosis Report 2019 Geneva.
(2019).
2. Horsburgh CR Jr, Barry CE, 3rd, Lange C. Treatment of tuberculosis.
N Engl J Med. (2015) 373:2149–60. doi: 10.1056/NEJMra14
13919
3. Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH,
DiNardo AR, et al. Perspectives for personalized therapy for patients
with multidrug-resistant tuberculosis. J Intern Med. (2018) 284:163–
88. doi: 10.1111/joim.12780
4. Salzer HJ, Wassilew N, Kohler N, Olaru ID, Gunther G, Herzmann
C, et al. Personalized medicine for chronic respiratory infectious
diseases: tuberculosis, nontuberculous mycobacterial pulmonary
Frontiers in Immunology | www.frontiersin.org 6 October 2020 | Volume 11 | Article 566608
Lange et al. Precision Medicine for TB
diseases, and chronic pulmonary aspergillosis. Respiration. (2016)
92:199–214. doi: 10.1159/000449037
5. Olaru ID, Lange C, Heyckendorf J. Personalized medicine for patients
with MDR-TB. J Antimicrob Chemother. (2016) 71:852–5. doi: 10.1093/jac/
dkv354
6. Consortium CR, the GP, Allix-Beguec C, Arandjelovic I, Bi L, Beckert
P, et al. Prediction of susceptibility to first-Line tuberculosis drugs by
DNA sequencing. N Engl J Med. (2018) 379:1403–15. doi: 10.1056/NEJMoa
1800474
7. DiNardo AR, Rajapakshe K, Gandhi T, Grimm S, Nishiguchi T, Heyckendorf
J, et al. Discerning divergent tuberculosis endotypes: a meta-analysis
and systematic review of individual patient data. medRxiv [priprint].
(2020). doi: 10.1101/2020.05.13.20100776
8. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. CD4 t cells
promote rather than control tuberculosis in the absence of PD-1-mediated
inhibition. J Immunol. (2011) 186:1598–607. doi: 10.4049/jimmunol.1003304
9. Roca FJ, Ramakrishnan L. TNF duallymediates resistance and susceptibility to
mycobacteria via mitochondrial reactive oxygen species. Cell. (2013) 153:521–
34. doi: 10.1016/j.cell.2013.03.022
10. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M,
et al. Genetics of human susceptibility to active and latent tuberculosis:
present knowledge and future perspectives. Lancet Infect Dis. (2018) 18:e64–
e75. doi: 10.1016/S1473-3099(17)30623-0
11. Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R.
Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm
Pharmacol Ther. (2012) 25:83–6. doi: 10.1016/j.pupt.2011.12.001
12. Heyckendorf J, Olaru ID, Ruhwald M, Lange C. Getting personal perspectives
on individualized treatment duration in multidrug-resistant and extensively
drug-resistant tuberculosis. Am J Respir Crit Care Med. (2014) 190:374–
83. doi: 10.1164/rccm.201402-0363PP
13. Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo
M, et al. Whole genome sequencing of Mycobacterium tuberculosis:
current standards and open issues. Nat Rev Microbiol. (2019) 17:533–
45. doi: 10.1038/s41579-019-0214-5
14. Ng KCS, Supply P, Cobelens FGJ, Gaudin C, Gonzalez-Martin J, de Jong
BC, et al. How well do routine molecular diagnostics detect rifampin
heteroresistance in Mycobacterium tuberculosis? J Clin Microbiol. (2019)
57:11. doi: 10.1128/JCM.00717-19
15. Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, et al. Direct
whole-Genome sequencing of sputum accurately identifies drug-Resistant
Mycobacterium tuberculosis faster than MGIT culture sequencing. J Clin
Microbiol. (2018) 56:18. doi: 10.1128/JCM.00666-18
16. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al.
Rapid genomic first- and second-line drug resistance prediction from clinical
Mycobacterium tuberculosis specimens using deeplex(R)-MyCTB. Eur Respir
J. (2020) doi: 10.1183/13993003.01796-2020. [Epub ahead of print].
17. Schleusener V, Koser CU, Beckert P, Niemann S, Feuerriegel S.Mycobacterium
tuberculosis resistance prediction and lineage classification from genome
sequencing: comparison of automated analysis tools. Sci Rep. (2017)
7:46327. doi: 10.1038/srep46327
18. Hunt M, Bradley P, Lapierre SG, Heys S, Thomsit M, Hall MB,
et al. Antibiotic resistance prediction for Mycobacterium tuberculosis
from genome sequence data with mykrobe. Wellcome Open Res. (2019)
4:191. doi: 10.12688/wellcomeopenres.15603.1
19. Angeby K, Jureen P, Kahlmeter G, Hoffner SE, Schon T. Challenging
a dogma: antimicrobial susceptibility testing breakpoints for
Mycobacterium tuberculosis. Bull World Health Organ. (2012)
90:693–8. doi: 10.2471/BLT.11.096644
20. Heyckendorf J, Andres S, Koser CU, Olaru ID, Schon T, Sturegard E, et al.
What is resistance? Impact of phenotypic versus molecular drug resistance
testing on therapy for multi- and extensively drug-resistant tuberculosis.
Antimicrob Agents Chemother. (2018) 62:2. doi: 10.1128/AAC.01550-17
21. Gygli SM, Keller PM, Ballif M, Blochliger N, Homke R, Reinhard M,
et al. Whole-Genome sequencing for drug resistance profile prediction
in Mycobacterium tuberculosis. Antimicrob Agents Chemother. (2019)
63:18. doi: 10.1128/AAC.02175-18
22. Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian
susceptibility to mycobacterial disease: genetic, immunological, and clinical
features of inborn errors of IFN-gamma immunity. Semin Immunol. (2014)
26:454–70. doi: 10.1016/j.smim.2014.09.008
23. Ehlers S. Role of tumour necrosis factor (TNF) in host defence against
tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum
Dis. (2003) 62(Suppl. 2):37–42. doi: 10.1136/ard.62.suppl_2.ii37
24. Tobin DM, Vary JC, Jr., Ray JP, Walsh GS, Dunstan SJ, et al. The lta4h locus
modulates susceptibility to mycobacterial infection in zebrafish and humans.
Cell. (2010) 140:717–30. doi: 10.1016/j.cell.2010.02.013
25. Tobin DM, Roca FJ, Oh SF, McFarland R, Vickery TW, Ray
JP, et al. Host genotype-specific therapies can optimize the
inflammatory response to mycobacterial infections. Cell. (2012)
148:434–46. doi: 10.1016/j.cell.2011.12.023
26. Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov
VV, et al. CD4 t Cell-Derived IFN-gamma plays a minimal role in
control of pulmonary Mycobacterium tuberculosis infection and must be
actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. (2016)
12:e1005667. doi: 10.1371/journal.ppat.1005667
27. Brighenti S, Bergman P, Martineau AR. Vitamin d and tuberculosis: where
next? J Intern Med. (2018) 284:145–62. doi: 10.1111/joim.12777
28. Tattersall WH. The survival of sputum-positive consumptives. A study
of 1,192 cases in a county borough between 1914 and 1940. Tubercle.
(1947) 28:109–14.
29. Furcolow ML, Emge ME, Bunnell IL. Depression of tuberculin and
histoplasmin sensitivity associated with critical illness. Public Health Rep.
(1948) 63:1290–8. doi: 10.2307/4586715
30. Michael L, Furcolow BH, Nelson WE, Palmer CE. Quantitative studies
of the tuberculin reaction: i. titration of tuberculin sensitivity and its
relation to tuberculous infection. Public Health Rep. (1941) 56:1082-
100. doi: 10.2307/4583745
31. DiNardo A, Rajapakshe K, Nishiguchi T, Mtetwa G, Grimm SL, Dlamini Q,
et al. DNA hyper-methylation during tuberculosis dampens host immune
responsiveness. J Clin Invest. (2020) 130:3113–123. doi: 10.1172/JCI134622
32. Sahiratmadja E, Alisjahbana B, de Boer T, Adnan I, Maya A, Danusantoso
H, et al. Dynamic changes in pro- and anti-inflammatory cytokine profiles
and gamma interferon receptor signaling integrity correlate with tuberculosis
disease activity and response to curative treatment. Infect Immun. (2007)
75:820–9. doi: 10.1128/IAI.00602-06
33. Singh A, Mohan A, Dey AB, Mitra DK. Inhibiting the programmed death
1 pathway rescues Mycobacterium tuberculosis -specific interferon gamma-
producing t cells from apoptosis in patients with pulmonary tuberculosis. J
Infect Dis. (2013) 208:603–15. doi: 10.1093/infdis/jit206
34. Warburg O,Wind F, Negelein E. The metabolism of tumors in the body. J Gen
Physiol. (1927) 8:519–30. doi: 10.1085/jgp.8.6.519
35. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V,
et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis
for trained immunity. Science. (2014) 345:1250684. doi: 10.1126/science.12
50684
36. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MAR,
Sheedy FJ, Gleeson LE, et al. Pyruvate kinase m2 regulates hif-1alpha
activity and IL-1beta induction and is a critical determinant of the
warburg effect in LPS-Activated macrophages. Cell Metab. (2015)
21:347. doi: 10.1016/j.cmet.2015.01.017
37. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE,
et al. Succinate dehydrogenase supports metabolic repurposing of
mitochondria to drive inflammatory macrophages. Cell. (2016) 167:457–70
e13. doi: 10.1016/j.cell.2016.08.064
38. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al.
Trained immunity: a program of innate immune memory in health and
disease. Science. (2016) 352:aaf1098. doi: 10.1126/science.aaf1098
39. Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al.
Immunometabolic pathways in BCG-Induced trained immunity. Cell Rep.
(2016) 17:2562–71. doi: 10.1016/j.celrep.2016.11.011
40. Padhi S, Ravichandran K, Sahoo J, Varghese RG, Basheer A.
Hemophagocytic lymphohistiocytosis: an unusual complication
in disseminated Mycobacterium tuberculosis. Lung India. (2015)
32:593–601. doi: 10.4103/0970-2113.168100
41. Prada-Medina CA, Fukutani KF, Pavan Kumar N, Gil-Santana L, Babu
S, Lichtenstein F, et al. Systems immunology of diabetes-Tuberculosis
Frontiers in Immunology | www.frontiersin.org 7 October 2020 | Volume 11 | Article 566608
Lange et al. Precision Medicine for TB
comorbidity reveals signatures of disease complications. Sci Rep. (2017)
7:1999. doi: 10.1038/s41598-017-01767-4
42. Lachmandas E, ThiemK, van denHeuvel C, Hijmans A, de Galan BE, Tack CJ,
et al. Patients with type 1 diabetes mellitus have impaired IL-1beta production
in response to Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis.
(2018) 37:371–80. doi: 10.1007/s10096-017-3145-y
43. Ronacher K, van Crevel R, Critchley JA, Bremer AA, Schlesinger LS, Kapur
A, et al. Defining a research agenda to address the converging epidemics
of tuberculosis and diabetes: part 2: underlying biologic mechanisms. Chest.
(2017) 152:174–80. doi: 10.1016/j.chest.2017.02.032
44. Trebak M, Kinet JP. Calcium signalling in t cells. Nat Rev Immunol. (2019)
19:154–69. doi: 10.1038/s41577-018-0110-7
45. Valdor R, Macian F. Induction and stability of the anergic phenotype in t cells.
Semin Immunol. (2013) 25:313–20. doi: 10.1016/j.smim.2013.10.010
46. Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun
overexpression in CAR t cells induces exhaustion resistance. Nature. (2019)
576:293–300. doi: 10.1038/s41586-019-1805-z
47. Yao C, Sun HW, Lacey NE, Ji Y, Moseman EA, Shih HY, et al. Single-cell RNA-
seq reveals TOX as a key regulator of CD8(+) t cell persistence in chronic
infection. Nat Immunol. (2019) 20:890–901. doi: 10.1038/s41590-019-0403-4
48. Seo H, Chen J, Gonzalez-Avalos E, Samaniego-Castruita D, Das A, Wang YH,
et al. TOX and TOX2 transcription factors cooperate with NR4A transcription
factors to impose CD8(+) t cell exhaustion. Proc Natl Acad Sci USA. (2019)
116:12410–5. doi: 10.1073/pnas.1905675116
49. Khan O, Giles JR, MCDonald S, Manne S, Ngiow SF, Patel KP, et al.
TOX transcriptionally and epigenetically programs CD8(+) t cell exhaustion.
Nature. (2019) 571:211–8. doi: 10.1038/s41586-019-1325-x
50. Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim HE, Roelli P, et al. TOX
reinforces the phenotype and longevity of exhausted t cells in chronic viral
infection. Nature. (2019) 571:265–9. doi: 10.1038/s41586-019-1326-9
51. Joosten SA, van Meijgaarden KE, Arend SM, Prins C, Oftung F, Korsvold
GE, et al. Mycobacterial growth inhibition is associated with trained innate
immunity. J Clin Invest. (2018) 128:1837–51. doi: 10.1172/JCI97508
52. Thye T, Vannberg FO, Wong SH, Owusu-Dabo E, Osei I, Gyapong J,
et al. Genome-wide association analyses identifies a susceptibility locus
for tuberculosis on chromosome 18q11.2. Nat Genet. (2010) 42:739–
41. doi: 10.1038/ng1011-1040a
53. Thye T, Owusu-Dabo E, Vannberg FO, van Crevel R, Curtis J, Sahiratmadja
E, et al. Common variants at 11p13 are associated with susceptibility to
tuberculosis. Nat Genet. (2012) 44:257–9. doi: 10.1038/ng.1080
54. Schurr E. The contribution of host genetics to tuberculosis pathogenesis.
Kekkaku. (2011) 86:17–28.
55. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies
supports the pharmacokinetic variability hypothesis for acquired drug
resistance and failure of antituberculosis therapy. Clin Infect Dis. (2012)
55:169–77. doi: 10.1093/cid/cis353
56. Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-
metabolising enzyme polymorphisms on the risk of anti-tuberculosis
drug-induced liver injury: a meta-analysis. PLoS ONE. (2012)
7:e47769. doi: 10.1371/journal.pone.0047769
57. Tobin DM. Host-Directed therapies for tuberculosis. Cold Spring Harb
Perspect Med. (2015) 5:10. doi: 10.1101/cshperspect.a021196
58. Thuong NTT, Heemskerk D, Tram TTB, Thao LTP, Ramakrishnan L, Ha
VTN, et al. Leukotriene a4 hydrolase genotype and HIV infection influence
intracerebral inflammation and survival from tuberculous meningitis. J Infect
Dis. (2017) 215:1020–8. doi: 10.1093/infdis/jix050
59. van Laarhoven A, Dian S, Ruesen C, Hayati E, Damen M, Annisa J,
et al. Clinical parameters, routine inflammatory markers, and LTA4H
genotype as predictors of mortality among 608 patients with tuberculous
meningitis in indonesia. J Infect Dis. (2017) 215:1029–39. doi: 10.1093/infdis/
jix051
60. Fava VM, Schurr E. Evaluating the impact of LTA4H genotype and immune
status on survival from tuberculous meningitis. J Infect Dis. (2017) 215:1011–
3. doi: 10.1093/infdis/jix052
61. Donovan J, Phu NH, Thao LTP, Lan NH, Mai NTH, Trang NTM,
et al. Adjunctive dexamethasone for the treatment of HIV-uninfected
adults with tuberculous meningitis stratified by leukotriene a4 hydrolase
genotype (LAST ACT): study protocol for a randomised double blind
placebo controlled non-inferiority trial. Wellcome Open Res. (2018)
3:32. doi: 10.12688/wellcomeopenres.14007.1
62. van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricano-
Ponce I, Ruesen C, et al. Cerebral tryptophan metabolism and outcome of
tuberculous meningitis: an observational cohort study. Lancet Infect Dis.
(2018) 18:526–35. doi: 10.1016/S1473-3099(18)30053-7
63. Hill AV. Evolution, revolution and heresy in the genetics of infectious
disease susceptibility. Philos Trans R Soc Lond B Biol Sci. (2012) 367:840–
9. doi: 10.1098/rstb.2011.0275
64. Ansari MA, Pedergnana V, C LCI, Magri A, Von Delft A, Bonsall D, et al.
Genome-to-genome analysis highlights the effect of the human innate and
adaptive immune systems on the hepatitis c virus. Nat Genet. (2017) 49:666–
73. doi: 10.1038/ng.3835
65. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early
interventions for diabetes related tuberculosis associate with hastened
sputum microbiological clearance in Virginia, USA. BMC Infect Dis. (2017)
17:125. doi: 10.1186/s12879-017-2226-y
66. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the
treatment of tuberculosis: an update. Drugs. (2014) 74:839–
54. doi: 10.1007/s40265-014-0222-8
67. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T.
Multidrug-resistant tuberculosis not due to noncompliance but to
between-patient pharmacokinetic variability. J Infect Dis. (2011)
204:1951–9. doi: 10.1093/infdis/jir658
68. Song T, Lee M, Jeon HS, Park Y, Dodd LE, Dartois V, et al. Linezolid trough
concentrations correlate with mitochondrial toxicity-Related adverse events
in the treatment of chronic extensively drug-Resistant tuberculosis. EBioMed.
(2015) 2:1627–33. doi: 10.1016/j.ebiom.2015.09.051
69. Magis-Escurra C, Later-Nijland H, Alffenaar J, Broeders J, Burger D, van
Crevel R, et al. Population pharmacokinetics and limited sampling strategy
for first-line tuberculosis drugs and moxifloxacin. Int J Antim Agents. (2014)
44:229–34. doi: 10.1016/j.ijantimicag.2014.04.019
70. van Beek SW, Ter Heine R, Keizer RJ, Magis-Escurra C, Aarnoutse
RE, Svensson EM. Personalized tuberculosis treatment through model-
Informed dosing of rifampicin. Clin Pharmacokinet. (2019) 58:815–
26. doi: 10.1007/s40262-018-00732-2
71. Han M, Jun SH, Lee JH, Park KU, Song J, Song SH. Method for
simultaneous analysis of nine second-line anti-tuberculosis drugs using
UPLC-MS/MS. J Antimicrob Chemother. (2013) 68:2066–73. doi: 10.1093/jac/
dkt154
72. Ruesen C, Riza AL, Florescu A, Chaidir L, Editoiu C, Aalders N, et al. Linking
minimum inhibitory concentrations to whole genome sequence-predicted
drug resistance in Mycobacterium tuberculosis strains from romania. Sci Rep.
(2018) 8:9676. doi: 10.1038/s41598-018-27962-5
73. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of
moxifloxacin in dried blood spots using LC-MS/MS and the impact of the
hematocrit and blood volume. J Chromatogr B Analyt Technol Biomed Life
Sci. (2011) 879:1063–70. doi: 10.1016/j.jchromb.2011.03.017
74. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR. Dried blood
spots: a new tool for tuberculosis treatment optimization. Curr Pharm Design.
(2011) 17:2931–9. doi: 10.2174/138161211797470174
75. Srivastava S, Gumbo T. In vitro and in vivomodeling of tuberculosis drugs and
its impact on optimization of doses and regimens. Curr Pharm Design. (2011)
17:2881–8. doi: 10.2174/138161211797470192
76. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B,
et al. Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis and
rifampicin resistance: a prospective multicentre diagnostic accuracy study.
Lancet Infect Dis. (2018) 18:76–84. doi: 10.1016/S1473-3099(17)30691-6
77. Nathavitharana RR, Cudahy PG, Schumacher SG, Steingart KR, Pai M,
Denkinger CM. Accuracy of line probe assays for the diagnosis of pulmonary
and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Eur Respir J. (2017) 49:1. doi: 10.1183/13993003.01075-2016
78. Bjerrum S, Schiller I, Dendukuri N, Kohli M, Nathavitharana RR, Zwerling
AA, et al. Lateral flow urine lipoarabinomannan assay for detecting active
tuberculosis in people living with HIV. Cochrane Database Syst Rev. (2019)
10:CD011420. doi: 10.1002/14651858.CD011420.pub3
79. Heyckendorf J, Labugger I, van der Merwe L, Garcia-Basteiro AL, Diacon AH,
Lange C. Serial measurements of transrenal mycobacterial DNA as indicators
Frontiers in Immunology | www.frontiersin.org 8 October 2020 | Volume 11 | Article 566608
Lange et al. Precision Medicine for TB
of the early bactericidal activity (EBA) of antituberculosis drugs. Tuberculosis.
(2017) 102:31–3. doi: 10.1016/j.tube.2016.10.005
80. Labugger I, Heyckendorf J, Dees S, Haussinger E, Herzmann C,
Kohl TA, et al. Detection of transrenal DNA for the diagnosis of
pulmonary tuberculosis and treatment monitoring. Infection. (2017)
45:269–76. doi: 10.1007/s15010-016-0955-2
81. Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D,
Alufandika-Moyo M, et al. Rapid urine-based screening for tuberculosis in
HIV-positive patients admitted to hospital in africa (STAMP): a pragmatic,
multicentre, parallel-group, double-blind, randomised controlled trial. Lancet.
(2018) 392:292–301. doi: 10.1016/S0140-6736(18)31267-4
82. Broger T, Nicol MP, Szekely R, Bjerrum S, Sossen B, Schutz C, et al. Diagnostic
accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay
for people living with HIV: a meta-analysis of individual in- and outpatient
data. PLoS Med. (2020) 17:e1003113. doi: 10.1371/journal.pmed.1003113
83. DiNardo AR, Kay AW, Maphalala G, Harris NM, Fung C, Mtetwa G, et al.
Diagnostic and treatment monitoring potential of a Stool-Based quantitative
polymerase chain reaction assay for pulmonary tuberculosis. Am J Trop Med
Hyg. (2018) 99:310–6. doi: 10.4269/ajtmh.18-0004
84. Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya
NE, et al. Assessment of the novel t-cell activation marker-
tuberculosis assay for diagnosis of active tuberculosis in children:
a prospective proof-of-concept study. Lancet Infect Dis. (2014)
14:931–8. doi: 10.1016/S1473-3099(14)70884-9
85. Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC,
Shankar S, et al. Four-gene pan-African blood signature predicts
progression to tuberculosis. Am J Respir Crit Care Med. (2018)
197:1198–208. doi: 10.1164/rccm.201711-2340OC
86. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM,
et al. A blood RNA signature for tuberculosis disease risk: a prospective
cohort study. Lancet. (2016) 387:2312–22. doi: 10.1016/S0140-6736(15)
01316-1
87. Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman
S, Chegou NN, et al. RISK6, a 6-gene transcriptomic signature of
TB disease risk, diagnosis and treatment response. Sci Rep. (2020)
10:8629. doi: 10.1101/19006197
88. Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas
A, et al. Concise whole blood transcriptional signatures for incipient
tuberculosis: a systematic review and patient-level pooled meta-analysis.
Lancet Respir Med. (2020) 8:395–406. doi: 10.1016/S2213-2600(19)
30282-6
89. Murphy K, Habib SS, Zaidi SMA, Khowaja S, Khan A, Melendez
J, et al. Computer aided detection of tuberculosis on chest
radiographs: an evaluation of the CAD4TB v6 system. Sci Rep. (2020)
10:5492. doi: 10.1038/s41598-020-62148-y
90. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, et al.
Assessment of the sensitivity and specificity of xpert MTB/RIF assay as an
early sputum biomarker of response to tuberculosis treatment. Lancet Resp
Med. (2013) 1:462–70. doi: 10.1016/S2213-2600(13)70119-X
91. Sabiiti W, Azam K, Kuchaka D, Mtafya B, Bowness R, Oravcova K, et al.
Improving diagnosis and monitoring of treatment response in pulmonary
tuberculosis using the molecular bacterial load assay (MBLA). bioRxiv. (2019)
2019:555995. doi: 10.3791/60460
92. Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R,
et al. Tuberculosis bacillary load, an early marker of disease severity:
the utility of tuberculosis molecular bacterial load assay. Thorax.
(2020) doi: 10.1136/thoraxjnl-2019-214238
93. Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N.
Molecular bacterial load assay, a culture-free biomarker for rapid and accurate
quantification of sputum Mycobacterium tuberculosis bacillary load during
treatment. J Clin Microbiol. (2011) 49:11. doi: 10.1128/JCM.00547-11
94. Ahmed MIM, Ziegler C, Held K, Dubinski I, Ley-Zaporozhan J, Geldmacher
C, et al. The TAM-TB assay-A promising TB immune-diagnostic
test with a potential for treatment monitoring. Front Pediatr. (2019)
7:27. doi: 10.3389/fped.2019.00027
95. Ahmed MIM, Ntinginya NE, Kibiki G, Mtafya BA, Semvua H, Mpagama
S, et al. Phenotypic changes on Mycobacterium tuberculosis -Specific CD4 t
Cells as surrogate markers for tuberculosis treatment efficacy. Front Immunol.
(2018) 9:2247. doi: 10.3389/fimmu.2018.02247
96. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, et al.
Persisting positron emission tomography lesion activity and Mycobacterium
tuberculosis MRNA after tuberculosis cure. Nature medicine. (2016) 22:1094–
100. doi: 10.1038/nm.4177
97. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson
EG, et al. Detection of tuberculosis recurrence, diagnosis and
treatment response by a blood transcriptomic risk signature in HIV-
Infected persons on antiretroviral therapy. Front Microbiol. (2019)
10:1441. doi: 10.3389/fmicb.2019.01441
98. Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, et al.
Host blood RNA signatures predict the outcome of tuberculosis treatment.
Tuberculosis (Edinb). (2017) 107:48–58. doi: 10.1016/j.tube.2017.08.004
Conflict of Interest: JH, MR, and CL have filed a patent for a 22-gene model to
predict the end of therapy of TB treatment (EP20158652.6).
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Lange, Aarnoutse, Chesov, van Crevel, Gillespie, Grobbel, Kalsdorf,
Kontsevaya, van Laarhoven, Nishiguchi, Mandalakas, Merker, Niemann, Köhler,
Heyckendorf, Reimann, Ruhwald, Sanchez-Carballo, Schwudke, Waldow and
DiNardo. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 9 October 2020 | Volume 11 | Article 566608
